FDA Clearance Tracker · P860057-S220
PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis
Last checked: Nov 20, 2026Latest source record: Apr 10, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Apr 10, 2025
Approved
Time to decision
161 days
Received Oct 31, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P860057-S220
- Device name
- PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis
- Applicant
- Edwards Lifesciences, LLC
- Applicant location
- Irvine, CA
- Received
- Oct 31, 2024
- Decided
- Apr 10, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P860057
Device type
- Device type
- replacement Heart-valve (DYE)
- Device class
- Class III
- Regulation
- 21 CFR 870.3925
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
modifications to the Instructions for Use to reflect the 8-year findings of the Post-Approval Study (PAS) Report submitted for the long term follow-up of the PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis prospective cohort study
Source documents
Other decisions for Edwards Lifesciences, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PASCAL Precision Transcatheter Valve Repair SystemPMA supplement
P220003-S029 · Decided Oct 20, 2026 · 180 days after receipt · Panel Track
Device type: Tricuspid valve repair device, percutaneously delivered (NPS) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.